FOLH1 and posterior cortical atrophy: Owing to its hepatobiliary excretion, a higher radiopharmaceutical uptake in the liver is observed with 18F-PSMA-1007 compared with other PSMA-targeted PET tracers; therefore, liver metastases of PCa may be missed by 18F-PSMA-1007 PET/CT, but this may happen in late PCa disease stages when rare cases of liver metastases can occur [25,26,29].